GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (OTCPK:GNIIF) » Definitions » EV-to-FCF

GNI Group (GNI Group) EV-to-FCF : 21.13 (As of May. 10, 2024)


View and export this data going back to 2013. Start your Free Trial

What is GNI Group EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, GNI Group's Enterprise Value is $647.2 Mil. GNI Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $30.6 Mil. Therefore, GNI Group's EV-to-FCF for today is 21.13.

The historical rank and industry rank for GNI Group's EV-to-FCF or its related term are showing as below:

GNIIF' s EV-to-FCF Range Over the Past 10 Years
Min: -401.53   Med: -33   Max: 812.86
Current: 22.85

During the past 13 years, the highest EV-to-FCF of GNI Group was 812.86. The lowest was -401.53. And the median was -33.00.

GNIIF's EV-to-FCF is ranked worse than
66.93% of 381 companies
in the Biotechnology industry
Industry Median: 6.23 vs GNIIF: 22.85

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-10), GNI Group's stock price is $12.93333. GNI Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $1.153. Therefore, GNI Group's PE Ratio for today is 11.22.


GNI Group EV-to-FCF Historical Data

The historical data trend for GNI Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group EV-to-FCF Chart

GNI Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 626.50 70.41 -404.31 -35.10 27.68

GNI Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.10 -26.32 -35.93 33.18 27.68

Competitive Comparison of GNI Group's EV-to-FCF

For the Biotechnology subindustry, GNI Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where GNI Group's EV-to-FCF falls into.



GNI Group EV-to-FCF Calculation

GNI Group's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=647.163/30.628
=21.13

GNI Group's current Enterprise Value is $647.2 Mil.
GNI Group's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $30.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GNI Group  (OTCPK:GNIIF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

GNI Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=12.93333/1.153
=11.22

GNI Group's share price for today is $12.93333.
GNI Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.153.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


GNI Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of GNI Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group (GNI Group) Business Description

Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group (GNI Group) Headlines